Lewis H. Bender, M.S., M.A., M.B.A.
Mr. Bender has over 28 years of biopharmaceutical leadership experience and has helped take products leveraging novel drug delivery techniques from discovery through product approval. Prior to founding Intensity Therapeutics, Mr. Bender was the CEO of Interleukin Genetics, a personalized medicine company, from January 2008 until August 2012. Prior to joining Interleukin, Mr. Bender held numerous positions at Emisphere Technologies, Inc., a drug delivery company specializing in the oral delivery of poorly absorbed molecules. His roles included: Interim President & CEO, President, Chief Technology Officer, Senior Vice President of Business Development, and Senior Vice President of Manufacturing and Process Development.
During his career, Mr. Bender has partnered with several major pharmaceutical and biotech companies using structures such as joint ventures, licensing and research collaboration agreements. In addition, Mr. Bender has been successful in raising capital from institutional investors through multiple types of transactions.